Recent Finacing
Recent Raise
Pulmocide is a clinical-stage biopharma developing inhaled small-molecule antivirals and antifungals (PC786, PC945/opelconazole) to treat RSV and Aspergillus-related lung diseases, including transplant and cystic fibrosis.
